Additional Grant. 26.2.1 Subject to Clause 26.2.4, commencing from the COD of Phase-I and until the expiry of 5 (five) years therefrom, the Authority shall provide financial support to the Concessionaire in accordance with Schedule 18 (the “Additional Grant”).
Additional Grant. With respect to each WCM Invention and Joint Invention and related Joint Results for which either Section 6.1 does not apply or Company or the Special Purpose Entity has not made an election to amend the License Agreements pursuant to Section 6.1, WCM hereby grants to Company the first option (each, an “Option”) to negotiate in good faith with WCM for a royalty-bearing, worldwide license, under WCM Patent Rights, WCM Results and WCM’s interest in Joint Patent Rights, to develop, make, have made, use, offer for sale, sell, have sold, and import Derived Products in the Field on terms that are commercially reasonable for academia to industry licenses; provided, however, that the license will be exclusive (or non-exclusive at Company’s discretion) with respect to WCM Patent Rights and Joint Patent Rights and will be non-exclusive with respect to WCM Results; and provided, further, that no such license will include any grant of exclusive rights that would be inconsistent with the National Institutes of Health’s Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources, as published at 64 Fed. Reg. 72090 and as may be amended from time to time.
Additional Grant. Xxxxxxxxx will be granted a non-qualified ---------------- option to purchase an additional 700,000 shares of the Company's Common Stock under, and pursuant to the terms of, the Company's 1996 Amended and Restated Stock Option Plan, including without limitation Section 11 thereof, at an exercise price equal to the fair market value (as determined by the Company's Board of Directors) on the date of grant (currently estimated to be $0.125 per share) (the "Additional Shares"). Such Additional Shares will vest and become ----------------- exercisable as follows, provided Xxxxxxxxx continues to provide services to the Company:
Additional Grant. Bio Control and AMS hereby agree to disclose to each other, the filing of any and all patent applications (including all patents issuing on such applications) covering electrical stimulation technology during a period from April 26, 2006, through April 26, 2009, subject to renewal for successive two (2) year terms thereafter, to the extent mutually agreed in writing by the parties prior to the end of the initial term or any renewal term, as the case may be. Bio Control and AMS agree that each will use good faith and commercially reasonable efforts (including after such period) to negotiate and enter into one or more non-exclusive license agreements with one another for all patent applications disclosed during the period, (i) granting AMS rights to any such patent applications filed by Bio Control during such period within the AMS Field of Use; and (ii) granting Bio Control rights to any such patent applications filed by AMS during such period outside of the AMS Field of Use. In all cases, such license agreements will provide for royalty payments at a rate that is commercially reasonable, commensurate with the value accorded by the parties, but not to exceed six percent (6%). Either party may terminate the parties’ obligations to disclose patent applications and to negotiate or to continue any ongoing negotiations under this Section 8 by notice to the other party following a Change in Control (as defined in the Asset Purchase Agreement) of either party, provided that such notice is given within thirty (30) days following the effective date of: (i) the Change in Control, if the termination notice is given by the party undergoing the Change in Control; or (ii) notice of the Change in Control given pursuant to the following sentence, if the termination notice is given by the party not undergoing the Change in Control. Each party covenants and agrees to provide the other with notice of any Change in Control no later than two (2) business days following the effective date of the Change in Control.
Additional Grant. Pursuant to the Merger Agreement, ALPP has reserved additional shares of ALPP Series C Preferred Stock with a grant date fair value equal to $250,000.00 (the “Advisor Pool”), which shall be reserved and available for grant to engage other former employees of Company prior to the merger (the “Former Employees”) for advisory services. ALPP may issue Restricted Stock Units from the Advisor Pool to Former Employees as it sees fit for a period of six (6) months from the Effective Date. The Company may opt instead to issue cash payments (the “Payments”) to Former Employees for consulting services in lieu of shares from the Advisor Pool. In this case, shares may be canceled from the Advisor Pool in value equal to the Payments. In the event that there are any shares remaining in the Advisor Pool on the earlier of (i) the six (6) month anniversary of the Effective Date or (ii) the termination of Consultant’s Services by the Company without Cause or by the Consultant for Good Reason, ALPP shall grant or cause the Company to grant Xx. Xxxx an additional number of Restricted Stock Units of ALPP with a grant date fair value equal to the value of the shares remaining in the Advisor Pool as of such date (the “Additional Restricted Stock Units”). For the avoidance of doubt, if the value of Series C Preferred Stock is set by ALPP at a value other than $3.50 per share, all Restricted Stock Unit grants will have their share counts proportionally adjusted.
Additional Grant. Upon the Effective Date of the IPO, the Company shall grant to Executive options to purchase a number of additional shares of Common Stock equal to 1% of the Common Stock (or such other type of stock of the Company as is registered in the IPO) outstanding on the effective date of the IPO, assuming that any overallotment option granted to the Underwriters in connection with the IPO is exercised in full. Such options shall be granted at an exercise price equal to the IPO offering price for such shares. To the extent possible, all of the Options shall qualify as incentive stock options under the Internal Revenue Code of 1986. All of the options to be granted pursuant to this Section are referred to herein collectively as the "Options" and shall be subject to the terms and conditions set forth below.
Additional Grant. In addition to the rights granted in the Soundrop Music Services Agreement, you hereby grant to Soundrop the non-exclusive right to sublicense Licensees, and to our designated Licensees the nonexclusive right, to Represent Your Authorized Content for use on a nonexclusive basis during the Term and throughout theuniverse in strict compliance with this Sync Distribution Addendum and any agreement separately entered into between Soundrop and a Licensee. Soundrop shall have sole discretion over the Licensees to be granted sublicenses pursuant to this Addendum.
Additional Grant. Advisor will be granted a non- ---------------- qualified option to purchase an additional 125,000 shares of the Company's Common Stock, at an exercise price equal to the fair market value (as determined by the Company's Board of Directors) on the date of grant (currently estimated to be $0.125 per share) (the "Additional Shares"). ----------------- Such Additional Shares will vest and become exercisable as follows, provided Advisor continues to provide services to the Company:
Additional Grant. In addition to the rights granted in the 9 Star Media Artist Agreement, you hereby grant to us and our Licensees, the non-exclusive right, during the Term and throughout the Authorized Territory, to:
